Inhibitors of HMG-CoA Reductase: Current and Future Prospects.
High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.
Singh
Narender
N
Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida 34987, USA.
Tamariz
Joaquín
J
Chamorro
Germán
G
Medina-Franco
Jose L
JL
D000081248:Allylbenzene Derivatives; D000840:Anisoles / Q000737:chemistry / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000737:chemistry* / Q000494:pharmacology; D001665:Binding Sites; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002784:Cholesterol / Q000378:metabolism; D030562:Databases, Protein; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000737:chemistry* / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000378:metabolism; D013329:Structure-Activity Relationship
D000081248:Allylbenzene Derivatives; D000840:Anisoles; D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; C012195:asarone; D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases